Alternative Antibiotics for MRSA and VRE Infections

Introduction to Alternative Antibiotics

The Infectious Diseases Society of America recommends tedizolid, daptomycin, tigecycline, and vancomycin as alternative antibiotics to linezolid for treating MRSA and VRE infections, with the specific choice depending on the infection site and patient factors 1

For patients with MRSA infections, the American College of Clinical Pharmacy recommends oral options such as tedizolid 200 mg once daily, with a shorter treatment duration of 6 days compared to 10 days for linezolid 1
The Society for Healthcare Epidemiology of America suggests trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg twice daily as an alternative for MRSA infections 2, 1
The Infectious Diseases Society of America recommends vancomycin 15-20 mg/kg IV every 8-12 hours as an intravenous option for MRSA infections 4, 1
Daptomycin 4-6 mg/kg IV once daily is recommended by the American College of Clinical Pharmacy for skin infections, and 8-12 mg/kg IV once daily for bacteremia 5, 1

The European Society of Clinical Microbiology and Infectious Diseases recommends daptomycin 8-12 mg/kg IV daily for VRE bacteremia, and in combination with β-lactams for optimal outcomes 7, 8
Tigecycline 100 mg IV loading dose, then 50 mg IV twice daily, is suggested by the Infectious Diseases Society of America for intra-abdominal infections due to VRE 7, 8
For uncomplicated urinary tract infections due to VRE, the American Urological Association recommends fosfomycin 3 g PO single dose or nitrofurantoin 100 mg PO every 6 hours 7, 8

The Pediatric Infectious Diseases Society recommends tedizolid for children >12 years, and clindamycin or vancomycin for younger children with MRSA 9
The Infectious Diseases Society of America advises considering alternatives to linezolid for long-term treatment due to potential for myelosuppression and neuropathy, although the exact alternatives are not specified in the provided citations
The American Thoracic Society notes that daptomycin is inactivated by pulmonary surfactant and should not be used for pneumonia 4
When treating VRE bacteremia with daptomycin, the Infectious Diseases Society of America recommends higher doses (8-12 mg/kg) for optimal outcomes 8

The Infectious Diseases Society of America notes that tedizolid has shown similar efficacy to linezolid with fewer adverse effects and once-daily dosing, although the exact comparison is not specified in the provided citations
Daptomycin has demonstrated non-inferiority to vancomycin and semi-synthetic penicillins for complicated skin infections, according to the American College of Clinical Pharmacy 5
For VRE infections, linezolid and daptomycin have shown comparable microbiological cure rates (91% vs 93%), as reported by the European Society of Clinical Microbiology and Infectious Diseases 8

The American Academy of Pediatrics advises that tetracyclines should not be used in children <8 years of age 2
The Infectious Diseases Society of America warns that clindamycin resistance is increasingly common in MRSA, and susceptibility testing is essential 1
The American Thoracic Society notes that daptomycin is inactivated by pulmonary surfactant and should not be used for pneumonia 4
When treating VRE bacteremia with daptomycin, the Infectious Diseases Society of America recommends higher doses (8-12 mg/kg) for optimal outcomes 8
For MRSA infections requiring coverage for both β-hemolytic streptococci and MRSA, the Infectious Diseases Society of America suggests options including clindamycin alone or TMP-SMX/tetracycline plus a β-lactam 3